<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2020-1S-4-8</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1394</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Polymorphic variants in the PVT1 locus affect multiple sclerosis severity</article-title><trans-title-group xml:lang="ru"><trans-title>Полиморфные варианты локуса PVT1 влияют на тяжесть течения рассеянного склероза</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Киселев</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kiselev</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии, нейрохирургии и медицинской генетики;</p><p>117997, Москва, ул. Островитянова, 1;354340, Сочи, Олимпийский проспект, 1;</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics</p><p>1, Ostrovityanov St, Moscow 117997; 1, Olympic Prosp., Sochi 354340</p></bio><email xlink:type="simple">kiselev.ivan.1991@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козин</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozin</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии, нейрохирургии и медицинской генетики;</p><p>117997, Москва, ул. Островитянова, 1;354340, Сочи, Олимпийский проспект, 1;</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics</p><p>1, Ostrovityanov St, Moscow 117997; 1, Olympic Prosp., Sochi 354340</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баулина</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Baulina</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии, нейрохирургии и медицинской генетики;</p><p>117997, Москва, ул. Островитянова, 1;354340, Сочи, Олимпийский проспект, 1;</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics</p><p>1, Ostrovityanov St, Moscow 117997; 1, Olympic Prosp., Sochi 354340</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлова</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlova</surname><given-names>G. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии, нейрохирургии и медицинской генетики;</p><p>117997, Москва, ул. Островитянова, 1;354340, Сочи, Олимпийский проспект, 1;</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics</p><p>1, Ostrovityanov St, Moscow 117997; 1, Olympic Prosp., Sochi 354340</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии, нейрохирургии и медицинской генетики;отдел нейроиммунологии</p><p>117997, Москва, ул. Островитянова, 1;117997, Москва, ул. Островитянова, 1, стр. 10</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics;Department of Neuroimmunology</p><p>1, Ostrovityanov St, Moscow 117997;1, Ostrovityanov St, Build. 10, Moscow 117997</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулакова</surname><given-names>О. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulakova</surname><given-names>O. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии, нейрохирургии и медицинской генетики;</p><p>117997, Москва, ул. Островитянова, 1;</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics</p><p>1, Ostrovityanov St, Moscow 117997</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фаворова</surname><given-names>О. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Favorova</surname><given-names>O. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии, нейрохирургии и медицинской генетики;</p><p>117997, Москва, ул. Островитянова, 1;</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery, and Medical Genetics</p><p>1, Ostrovityanov St, Moscow 117997</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; &#13;
Научно-технологический университет «Сириус»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;&#13;
Sirius University of Science and Technology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; &#13;
ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;&#13;
Federal Center for the Brain and Neurotechnologies, Federal Biomedical Agency of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>05</day><month>08</month><year>2020</year></pub-date><volume>12</volume><issue>1S</issue><issue-title>Спецвыпуск: рассеянный склероз</issue-title><fpage>4</fpage><lpage>8</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kiselev I.S., Kozin M.S., Baulina N.M., Pavlova G.V., Boyko A.N., Kulakova O.G., Favorova O.O., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Киселев И.С., Козин М.С., Баулина Н.М., Павлова Г.В., Бойко А.Н., Кулакова О.Г., Фаворова О.О.</copyright-holder><copyright-holder xml:lang="en">Kiselev I.S., Kozin M.S., Baulina N.M., Pavlova G.V., Boyko A.N., Kulakova O.G., Favorova O.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1394">https://nnp.ima-press.net/nnp/article/view/1394</self-uri><abstract><p>Multiple sclerosis (MS) is a chronic autoimmune disease, in the pathogenesis of which the concurrence of demyelination of central nervous system (CNS) axons and neurodegeneration plays a role and which is accompanied by progressive neurological dysfunction. Long-term monitoring of patients with MS is needed to rate its severity according to existing scales; it is therefore very relevant to search for genomic markers that can predict the rate of disease progression at early stages. The impact of polymorphic variants in the PVT1 locus on MS severity has not been previously studied.</p><sec><title>Objective</title><p>Objective: to analyze the association of the polymorphic variants rs4645948 in the MYC gene and rs2114358 and rs4410871) in the PVT1 genes with MS severity according to the Multiple Sclerosis Severity Scale (MSSS) separately and as part of biallelic combinations, as well as the possible linkage disequilibrium of the studied single nucleotide polymorphisms for establishing the independence of the observed associations.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. The investigation enrolled 468 Russian MS patients who did not take immunomodulating drugs before blood testing. The patients were divided into two groups: 1) relatively mild MS (MSSS ≤3.5) and 2) relatively severe MS (MSSS &gt;3.5). The polymorphic variants in the PVT1 locus were genotyped by a real-time polymerase chain reaction assay.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. In the MS study group, the carriage of the allele of PVT1 (rs2114358)*G turned out to be associated with the severe course of the disease (pf=0.042; odds ratio (OR)=1.41). The significance of the association increases in the simultaneous carriage of this allele with another variant of the same gene – PVT1 (rs4410871)*T (pf=0.024; OR=1.58). There was no linkage disequilibrium between the components of the biallelic combination.</p></sec><sec><title>Conclusion</title><p>Conclusion. The polymorphic variants in the PVT1 locus are associated with the severity of MS.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Рассеянный склероз (РС) – хроническое заболевание аутоиммунной природы, в патогенезе которого играет роль сочетание демиелинизации аксонов в ЦНС и нейродегенерации и которое сопровождается прогрессирующей неврологической дисфункцией. Для определения тяжести течения РС по существующим шкалам требуется длительное наблюдение за больными, поэтому поиск геномных маркеров, позволяющих предсказать скорость прогрессирования заболевания на ранних стадиях, весьма актуален. Влияние полиморфных вариантов локуса PVT1 на тяжесть течения РС ранее не изучалось.</p><p>Цель исследования – анализ ассоциации полиморфных вариантов генов MYC (rs4645948) и PVT1 (rs2114358, rs4410871) с тяжестью течения РС по Multiple Sclerosis Severity Scale (MSSS) по отдельности и в составе биаллельных сочетаний; анализ возможного неравновесного сцепления исследованных однонуклеотидных полиморфизмов для установления независимости наблюдаемых ассоциаций.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. В исследование включено 468 русских пациентов с РС, не принимавших иммуномодулирующие препараты до момента анализа крови. Пациенты были разделены на две группы: с относительно легким (MSSS ≤3,5) и с относительно тяжелым (MSSS &gt;3,5) течением РС. Генотипирование полиморфных вариантов локуса PVT1 проводили методом полимеразной цепной реакции в реальном времени.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. В исследованной группе больных РС носительство аллеля PVT1 (rs2114358)*G оказалось ассоциировано с тяжелым течением заболевания (pf=0,042, отношение шансов, ОШ=1,41). Значимость ассоциации повышается в случае одновременного носительства этого аллеля с другим вариантом того же гена – PVT1 (rs4410871)*T (pf=0,024, ОШ=1,58). Неравновесное сцепление между компонентами биаллельного сочетания отсутствует.</p></sec><sec><title>Заключение</title><p>Заключение. Полиморфные варианты локуса PVT1 ассоциируются с тяжестью течения РС.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рассеянный склероз</kwd><kwd>шкала тяжести рассеянного склероза</kwd><kwd>генетический полиморфизм</kwd><kwd>анализ ассоциации</kwd><kwd>мультилокусный анализ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>multiple sclerosis</kwd><kwd>Multiple Sclerosis Severity Scale</kwd><kwd>genetic polymorphism</kwd><kwd>association analysis</kwd><kwd>multilocus analysis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке Российского фонда фундаментальных исследований в рамках научного проекта №19-315-51003.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kozin MS, Kulakova OG, Favorova OO. Involvement of mitochondria in neurodegeneration in multiple sclerosis. Biochemistry (Mosc). 2018 Jul;83(7):813-30. doi: 10.1134/S0006297918070052.</mixed-citation><mixed-citation xml:lang="en">Kozin MS, Kulakova OG, Favorova OO. Involvement of mitochondria in neurodegeneration in multiple sclerosis. Biochemistry (Mosc). 2018 Jul;83(7):813-30. doi: 10.1134/S0006297918070052.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Boyko A, Smirnova N, Petrov S, Gusev E. Epidemiology of MS in Russia, a historical review. Mult Scler Demyelinating Disord. 2016;1(1):13.</mixed-citation><mixed-citation xml:lang="en">Boyko A, Smirnova N, Petrov S, Gusev E. Epidemiology of MS in Russia, a historical review. Mult Scler Demyelinating Disord. 2016;1(1):13.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Confavreux C, Vukusic S. The clinical course of multiple sclerosis. In: Handbook of Clinical Neurology. Vol 122. Elsevier B.V.; 2014: P. 343-69.</mixed-citation><mixed-citation xml:lang="en">Confavreux C, Vukusic S. The clinical course of multiple sclerosis. In: Handbook of Clinical Neurology. Vol 122. Elsevier B.V.; 2014: P. 343-69.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Roxburgh RHSR, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology. 2005 Apr 12;64(7):1144-51. doi: 10.1212/01.WNL.0000156155.19270.F8.</mixed-citation><mixed-citation xml:lang="en">Roxburgh RHSR, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology. 2005 Apr 12;64(7):1144-51. doi: 10.1212/01.WNL.0000156155.19270.F8.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Oksenberg JR. Decoding multiple sclerosis: an update on genomics and future directions. Expert Rev Neurother. 2013 Dec;13(12 Suppl): 11-9. doi: 10.1586/14737175.2013.865867.</mixed-citation><mixed-citation xml:lang="en">Oksenberg JR. Decoding multiple sclerosis: an update on genomics and future directions. Expert Rev Neurother. 2013 Dec;13(12 Suppl): 11-9. doi: 10.1586/14737175.2013.865867.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Patsopoulos NA, Baranzini SE, Santaniello A, et al. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019 Sep 27;365(6460): eaav7188. doi: 10.1126/science.aav7188.</mixed-citation><mixed-citation xml:lang="en">Patsopoulos NA, Baranzini SE, Santaniello A, et al. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019 Sep 27;365(6460): eaav7188. doi: 10.1126/science.aav7188.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">George MF, Briggs FBS, Shao X, et al. Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.</mixed-citation><mixed-citation xml:lang="en">George MF, Briggs FBS, Shao X, et al. Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Javor J, Shawkatova I, Durmanova V, et al. TNFRSF1A polymorphisms and their role in multiple sclerosis susceptibility and severity in the Slovak population. Int J Immunogenet. 2018 Jul 16. doi: 10.1111/iji.12388. Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">Javor J, Shawkatova I, Durmanova V, et al. TNFRSF1A polymorphisms and their role in multiple sclerosis susceptibility and severity in the Slovak population. Int J Immunogenet. 2018 Jul 16. doi: 10.1111/iji.12388. Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bashinskaya V V, Kulakova OG, Kiselev IS, et al. GWAS-identified multiple sclerosis risk loci involved in immune response: Validation in Russians. J Neuroimmunol. 2015 May 15;282: 85-91. doi: 10.1016/j.jneuroim.2015.03.015. Epub 2015 Mar 17.</mixed-citation><mixed-citation xml:lang="en">Bashinskaya V V, Kulakova OG, Kiselev IS, et al. GWAS-identified multiple sclerosis risk loci involved in immune response: Validation in Russians. J Neuroimmunol. 2015 May 15;282: 85-91. doi: 10.1016/j.jneuroim.2015.03.015. Epub 2015 Mar 17.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kozin MS, Kulakova OG, Kiselev IS, et al. Variants of mitochondrial genome and risk of multiple sclerosis development in Russians. Acta Naturae. Oct-Dec 2018;10(4):79-86.</mixed-citation><mixed-citation xml:lang="en">Kozin MS, Kulakova OG, Kiselev IS, et al. Variants of mitochondrial genome and risk of multiple sclerosis development in Russians. Acta Naturae. Oct-Dec 2018;10(4):79-86.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Rhizobium GE. Complete Genome Sequence of the Sesbania Symbiont and Rice. Nucleic Acids Res. 2013;1(1256879):13-4.</mixed-citation><mixed-citation xml:lang="en">Rhizobium GE. Complete Genome Sequence of the Sesbania Symbiont and Rice. Nucleic Acids Res. 2013;1(1256879):13-4.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kunkl M, Sambucci M, Ruggieri S, et al. CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis. Cells. 2019 Jun 11;8(6):575. doi: 10.3390/cells8060575.</mixed-citation><mixed-citation xml:lang="en">Kunkl M, Sambucci M, Ruggieri S, et al. CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple Sclerosis. Cells. 2019 Jun 11;8(6):575. doi: 10.3390/cells8060575.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Guo Z, Wang Y, Zhao Y, et al. A functional 5’-UTR polymorphism of MYC contributes to nasopharyngeal carcinoma susceptibility and chemoradiotherapy induced toxicities. J Cancer. 2019 Jan 1;10(1):147-55. doi: 10.7150/jca.28534. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Guo Z, Wang Y, Zhao Y, et al. A functional 5’-UTR polymorphism of MYC contributes to nasopharyngeal carcinoma susceptibility and chemoradiotherapy induced toxicities. J Cancer. 2019 Jan 1;10(1):147-55. doi: 10.7150/jca.28534. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.</mixed-citation><mixed-citation xml:lang="en">Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ghetti M, Vannini I, Storlazzi CT, et al. Linear and circular PVT1 in hematological malignancies and immune response: Two faces of the same coin. Mol Cancer. 2020 Mar 30; 19(1):69. doi: 10.1186/s12943-020-01187-5.</mixed-citation><mixed-citation xml:lang="en">Ghetti M, Vannini I, Storlazzi CT, et al. Linear and circular PVT1 in hematological malignancies and immune response: Two faces of the same coin. Mol Cancer. 2020 Mar 30; 19(1):69. doi: 10.1186/s12943-020-01187-5.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ghafouri-Fard S, Omrani MD, Taheri M. Long noncoding RNA PVT1: A highly dysregulated gene in malignancy. J Cell Physiol. 2020 Feb;235(2):818-35. doi: 10.1002/jcp.29060. Epub 2019 Jul 11.</mixed-citation><mixed-citation xml:lang="en">Ghafouri-Fard S, Omrani MD, Taheri M. Long noncoding RNA PVT1: A highly dysregulated gene in malignancy. J Cell Physiol. 2020 Feb;235(2):818-35. doi: 10.1002/jcp.29060. Epub 2019 Jul 11.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang CW, Wu X, Liu D, et al. Long noncoding RNA PVT1 knockdown suppresses fibroblast-like synoviocyte inflammation and induces apoptosis in rheumatoid arthritis through demethylation of sirt6. J Biol Eng. 2019 Jul 2;13:60. doi: 10.1186/s13036-019-0184-1. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Zhang CW, Wu X, Liu D, et al. Long noncoding RNA PVT1 knockdown suppresses fibroblast-like synoviocyte inflammation and induces apoptosis in rheumatoid arthritis through demethylation of sirt6. J Biol Eng. 2019 Jul 2;13:60. doi: 10.1186/s13036-019-0184-1. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ali M, Shaker O, Khalefa A, et al. Serum long noncoding RNAs FAS-AS1 &amp;amp; PVT1 are novel biomarkers for systemic lupus erythematous. Br J Biomed Sci. 2020 Jul 2;1-5. doi: 10.1080/09674845.2020.1765459. Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">Ali M, Shaker O, Khalefa A, et al. Serum long noncoding RNAs FAS-AS1 &amp; PVT1 are novel biomarkers for systemic lupus erythematous. Br J Biomed Sci. 2020 Jul 2;1-5. doi: 10.1080/09674845.2020.1765459. Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kiselev I, Bashinskaya V, Baulina N, et al. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability. Mult Scler Relat Disord. 2019 Apr;29:130-36. doi: 10.1016/j.msard.2019.01.033. Epub 2019 Jan 24.</mixed-citation><mixed-citation xml:lang="en">Kiselev I, Bashinskaya V, Baulina N, et al. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability. Mult Scler Relat Disord. 2019 Apr;29:130-36. doi: 10.1016/j.msard.2019.01.033. Epub 2019 Jan 24.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kiselev IS, Kulakova OG, Baulina NM, et al. Variability of the MIR196A2 Gene as a Risk Factor in Primary-Progressive Multiple Sclerosis Development. Mol Biol (Mosk). Mar-Apr 2019;53(2):282-89. doi: 10.1134/S0026898419020071.</mixed-citation><mixed-citation xml:lang="en">Kiselev IS, Kulakova OG, Baulina NM, et al. Variability of the MIR196A2 Gene as a Risk Factor in Primary-Progressive Multiple Sclerosis Development. Mol Biol (Mosk). Mar-Apr 2019;53(2):282-89. doi: 10.1134/S0026898419020071.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
